Drug Database
DO

donepezil (E 2022 / TK023 / TK 023)

✓ Approved

Eisai Co., Ltd. · ACHE · Small Molecule

What is donepezil?

donepezil is a small molecule developed by Eisai Co., Ltd.. It is approved for therapeutic indications via transdermal.

Drug Profile

Brand NamesE 2022, TK023, TK 023
CompanyEisai Co., Ltd.
Drug ClassSmall Molecule
Molecular TargetACHE
RouteTransdermal
StatusApproved

Mechanism of Action

Molecular Targets

donepezil acts on 1 molecular target:

ACHEacetylcholinesterase (Cartwright blood group) (N-ACHE, ACEE)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

donepezil is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Nervous system disordersDementia Alzheimer's typePhase I

Related Research Articles

PubMedInternational journal of retina and vitreous2026-09-19

Microaneurysm segmentation in early diabetic retinopathy: a localized patch-based U-Net approach to overcome microscopic lesion oversight.

Atada Likhitha D LD, Manjunath Madhura Prakash MP, Prasad Deepthi K DK, Srinivasan Venkatakrishnan V

Diabetic Retinopathy (DR) is a leading cause of vision impairment and a major long-term microvascular complication of diabetes. Early detection and prevention of diabetes-related complications through advanced imaging and software-assisted patient management remain important clinical priorities. Microaneurysms (MAs) are the earliest and most subtle indicators of DR, but their small size and low contrast often lead to missed detection during manual fundus examination, delaying intervention. Automated MA segmentation is therefore essential for large-scale DR screening. We conducted a controlled empirical evaluation of localized patch-based training for microaneurysm (MA) segmentation, benchmarking a compact, imbalance-aware U-Net model including learnable transposed-convolution up-sampling against a full-image U-Net trained on identical data. Fundus images and corresponding MA masks were divided into non-overlapping 256 × 256 patches, increasing MA pixel density per training sample by approximately 60-fold relative to full-image input thereby directly targeting the extreme class imbalance that causes full-image models to collapse to all-background predictions. The model was trained and evaluated on the publicly available IDRiD [Indian Diabetic Retinopathy Image Dataset] and DDR [Dataset for Diabetic Retinopathy] datasets. Performance was assessed using Intersection over Union (IoU), Dice coefficient, accuracy, recall, and precision. Performance was evaluated on a representative held-out subset of 100 images selected from an independent pool of 514 MA-annotated test images spanning the IDRiD and DDR datasets. The patch-based model achieved an overall pixel-level accuracy of 99.89%, a Dice coefficient of 76.9%, IoU of 63.2%, recall (sensitivity) of 69.1% and precision of 88.7%, while the full-image U-Net trained on the same data failed to recover any MA pixels (IoU = 0, Dice = 0) despite comparable pixel accuracy thereby demonstrating that overlap-based metrics, not accuracy, are the decisive criterion for this task. Per-image lesion-coverage analysis showed a mean match rate of approximately 60% of annotated MA contours, providing a clinically interpretable read-out beyond pixel overlap. This controlled empirical evaluation demonstrates that localized patch-based training is an effective and computationally efficient strategy for overcoming the extreme class imbalance that causes conventional full-image U-Nets to systematically miss microaneurysms. The proposed patch-based U-Net showed promising microaneurysm segmentation performance on a held-out subset of IDRiD and DDR images; further evaluation on the additional datasets and independent external cohorts can aid in the clinical screening utility.

PubMedNature cancer2026-09-19

A universal visual foundation model for computational cytopathology.

Zheng Xueyi X, Zheng Ke K, Wang Jue J, Zhang Xinke X et al.

Cytopathology is central to cancer screening and diagnosis but remains labor-intensive, motivating the development of scalable computational solutions. Here, we present CROWN (Cytology visual foundation netwoRk Optimized With self-supervised learNing), a universal visual foundation model for computational cytopathology. CROWN was pretrained on more than 10 million cytology image patches using a DINOv2-based self-supervised framework, without requiring manual annotations during pretraining. We evaluated CROWN in 202 task-setting combinations spanning classification, segmentation, detection, retrieval and slide-level prediction across private institutional cohorts and public datasets. CROWN achieved the best overall performance among established pretrained encoders across diverse benchmark settings, with accuracy exceeding 95% in 48 patch-level classification evaluations and 98% in 22 of them. These findings support CROWN as a scalable visual backbone for general-purpose computational cytopathology across heterogeneous datasets and task settings.

PubMedAllergy2026-09-19

Legends of Allergy and Immunology: Johannes Ring.

Traidl-Hoffmann Claudia C

Johannes Ring has shaped allergology for more than five decades. His scientific work ranges from early studies on anaphylaxis and drug hypersensitivity to atopic dermatitis, the atopy patch test and the role of environmental factors in allergic disease. But this is only one part of his legacy. As a clinician, the patient was always at the centre of his thinking, and many of his research questions came directly from clinical observation. As a mentor, he encouraged young physicians and scientists to be curious, critical of their own results and, most importantly, to find their own scientific path. Many of his former trainees today hold leading positions in allergology and dermatology across Europe. For me, Johannes Ring has been a mentor for more than two decades-and still is. At 80, he has taken on a new role in Davos. He is clearly not finished yet.

PubMedJournal of biomaterials science. Polymer edition2026-09-18

Engineering centrifugally spun nanofibrous matrices as high-performance transdermal patches for accelerated Alzheimer's treatment.

Gaber Dalia A DA

This study aimed to develop and optimize a centrifugally spun polycaprolactone/poly(vinyl alcohol) (PCL/PVA) nanofibrous transdermal patch containing polyethylene glycol 400 (PEG 400) and oleic acid to improve rivastigmine delivery for the long-term management of Alzheimer's disease. Rivastigmine-loaded nanofibrous patches were fabricated by centrifugal spinning and characterized using scanning electron microscopy (SEM), differential scanning calorimetry (DSC), and attenuated total reflectance-Fourier transform infrared spectroscopy (ATR-FTIR). Mechanical properties, drug release, ex vivo skin permeation and deposition, dermal irritation, pharmacokinetics in New Zealand White rabbits, and stability were systematically evaluated. The optimized formulation (F5) produced uniform, bead-free nanofibers (1.7 ± 0.3 μm) with rivastigmine molecularly dispersed in an amorphous state within the polymeric matrix. The patch exhibited favorable mechanical properties, sustained drug release, enhanced ex vivo skin permeation (0.50 ± 0.04 mg/cm2 at 24 h), and increased drug deposition within the viable epidermis and dermis, indicating cutaneous reservoir formation. Dermal irritation was negligible (Primary Irritation Index = 0.08). Pharmacokinetic studies demonstrated prolonged systemic absorption (Tmax = 6.0 ± 1.0 h) and approximately five-fold greater systemic exposure (AUC0-∞ = 345 ± 28 ng·h/mL) than the oral formulation (67 ± 9 ng·h/mL, p < 0.05).The optimized centrifugally spun nanofibrous patch provided sustained rivastigmine delivery, excellent dermal biocompatibility, enhanced skin deposition, and improved systemic bioavailability, supporting its potential as a scalable transdermal platform for long-term Alzheimer's disease therapy.

PubMedEuropean archives of paediatric dentistry : official journal of the European Academy of Paediatric Dentistry2026-09-18

The efficacy of transdermal melatonin in dental anxiety in children: a randomised placebo-controlled clinical trial.

Wahba Nour N, Nagi Basma Mahmoud BM, El-Baraky Iman Ali IA, El-Motayam Ahmed Kamal AK

Dental anxiety, a prevalent barrier to optimum dental care, frequently necessitates pharmacological intervention. Melatonin appears to be a safe anxiolytic in medical settings but remains underexplored in paediatric dental anxiety management. Our objective was to evaluate the efficacy of transdermal melatonin patches in managing dental anxiety in children undergoing invasive dental treatment. 52 children aged 5-7 years undergoing dental treatment requiring infiltration local anaesthesia (LA) were randomly assigned to receive either 2 mg transdermal melatonin patches (n = 26) or placebo patches (n = 26), applied to the forearm 30 min before treatment. Outcomes included physiological parameters (heart rate (HR), systolic blood pressure (SPB), diastolic blood pressure (DPB), peripheral oxygen saturation (SpO2)), and dental anxiety by self-reported Facial Image Scale (FIS). All outcomes were recorded at baseline (T1), post-administration (T2), post-LA (T3), and end of treatment (T4). Transdermal melatonin did not significantly affect either the physiological parameters or the FIS compared to placebo at any timepoint. Intragroup analysis revealed that melatonin protected against the rise in HR and DBP associated with LA injection observed in the placebo group following LA injection. ANCOVA indicated a moderate, statistically significant effect of melatonin on HR at T3 independent of baseline HR (effect size = 9%, P = 0.033, power = 58%). Melatonin induced a transient increase in SpO₂ noted post-administration (mean difference 0.96%, P = 0.019). Transdermal melatonin patches provided modest cardioprotective effects against the haemodynamic stress of dental injections during paediatric dental procedures but did not significantly reduce self-reported dental anxiety.

PubMedJournal of analytical toxicology2026-09-18

Urinary detection and metabolites profiles of trenbolone and metenolone following trace-level dermal exposure.

Krombholz Sophia S, Angelis Yiannis A YA, Fußhöller Gregor G, Thevis Mario M

Recent studies have demonstrated that dermal exposure to anabolic androgenic steroids (AAS) can result in adverse analytical findings (AAFs) in doping controls with a comparably long detectability of the parent compound and/or their metabolites in urine samples. Transdermal absorption is influenced by multiple factors, including physicochemical properties of the substance and solubility; but is largely driven by the degree of exposure, i.e. amount of substance applied. Therefore, this study aimed to investigate the detectability and urinary excretion profiles of trenbolone (TREN) and metenolone (MET) after dermal exposure to microgram quantities of these frequently abused AAS. Controlled excretion studies were conducted with healthy male volunteers, and each participant received a single dose of 50 µg TREN or MET via dermal application to the forearm. Urine samples were collected and analyzed for the parent compounds and their metabolites by liquid chromatography coupled to high resolution tandem mass spectrometry (LC-HRMS/MS). To enhance sensitivity and product ion formation, derivatization with Girard's reagent T was employed for MET and its metabolites. Following administration of transdermal microdoses, both substances and/or their metabolites were detectable in the urine samples of all participants. For TREN, predominantly the established main metabolite epitrenbolone was identified, with maximum concentrations up to 2.6 ng/ml and a detection window of up to three days post-application. Maximum concentrations of MET ranged from 0.1-1.2 ng/ml. Notably, particularly the sulfoconjugated metabolite of MET remained detectable for over a week in one volunteer. Metabolite profiles were compared with those of urine samples obtained after oral administration of the steroids to assess potential differences. Considering the increasing number of alleged transdermal contamination cases, the results provide important analytical data to better assess the plausibility of such claims.

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about donepezil